Hydroxy methoxy benzaldehyde from Sesbania grandilfora inhibits the advanced glycation end products (AGEs)-mediated fibrillation in hemoglobin

Green Synthesising ZnO Nanoparticle Using Sesbania grandiflora and Their Evaluation of Anti-diabetic Anti-advanced Glycation End Products and Cytotoxic Effects

Nanotechnology is an emerging area of science with diverse implementations, including medicine and drug delivery. Often for drug delivery, nanoparticles and nanocarriers were used. Diabetes mellitus is a metabolic disease with numerous complications, including advanced glycation end products (AGEs). AGEs advance neurodegeneration, obesity, renal dysfunction, retinopathy, and many more. Here, we have used zinc oxide nanoparticles synthesised with Sesbania grandiflora (hummingbird tree). ZnO nanoparticles and S. grandiflora are known for their biocompatibility and medicinal property, such as anti-cancer, anti-microbial, anti-diabetic, and anti-oxidant. So, we analysed the anti-diabetic, anti-oxidant, anti-AGEs, and cytotoxic effects of green synthesised and characterised ZnO nanoparticles with S. grandiflora (SGZ) and the leaf extract of S. grandiflora. Characterisation results indicated the synthesis of ZnO Nps at maximum concentration; the anti-oxidant assay showed 87.5% free radicle scavenging with DPPH. Additionally, anti-diabetic (72% α-amylase and 65% of α-glucosidase inhibition) and cell viability also exhibited promising results. In conclusion, SGZ can reduce the absorption of carbohydrates from the diet, elevate glucose uptake, and prevent protein glycation. So, it could be a potential tool for treating diabetes, hyperglycemia, and AGE-related diseases.

Competent antioxidant and antiglycation properties of zinc oxide nanoparticles (ZnO-NPs) phyto-fabricated from aqueous leaf extract of Boerhaavia erecta L

During the present century, plant-based zinc oxide nanoparticles (ZnO-NPs) are exploited extensively for their vast biological properties due to their unique characteristic features and eco-friendly nature. Diabetes is one of the fast-growing human diseases/abnormalities worldwide, and the need for new/ novel antiglycation products is the need of the hour. The study deals with the phyto-fabrication of ZnO-NPs from Boerhaavia erecta, a medicinally important plant, and to evaluate their antioxidant and antiglycation ability in vitro. UV-visible spectroscopy (UV-Vis), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) were used to characterize the phyto-fabricated ZnO-NPs. The characterization of nanoparticles revealed that the particles showed an absorption peak at 362 nm and band gap energy of 3.2 eV, approximately 20.55 nm in size, with a ZnO elemental purity of 96.61%. The synthesized particles were found agglomerated when observed under SEM, and the FT-IR studies proved that the phyto-constituents of the extract involved during the different stages (reduction, capping, and stabilization) of nanoparticles synthesis. The antioxidant and metal chelating activities confirmed that ZnO-NPs could inhibit the free radicals generated, which was dose-dependent with an IC₅₀ value between 1.81 and 1.94 mg mL^-1, respectively. In addition, the phyto-fabricated nanoparticles blocked the formation of advanced glycation end products (AGEs) as noticed through inhibition of Amadori products, trapping of reactive dicarbonyl intermediate and breaking the cross-link of glycated protein. It was also noted that the phyto-fabricated ZnO-NPs significantly prevented the damage of red blood corpuscles (RBCs) induced by MGO. The present study's findings will provide an experimental basis for exploring ZnO-NPs in diabetes-related complications.

Differential effect of biophenols on attenuation of AGE-induced hemoglobin aggregation

Despite most studied activities of natural biophenols rely on antioxidant properties, little clues explored their key structural components with regard to opposing action on glycation-induced aggregation. Herein, human hemoglobin (hHb)/fructose system used to decipher if structural peculiarities of two biophenols "chlorogenic acid (CGA) and curcumin (CUR)" are effective toward AGEs-bridged aggregate formation. Suppression in amyloid cross-β formation was monitored by CD spectroscopy, fluorescence microscopy, ANS and AGE fluorescence. Reduction in molten globule structure of modified-Hb by CGA was corroborated with helix structure, thiol group and lysine residues content estimation for native, glycated and biophenols treated samples. ThT and Congo red assays showed the cross-β breaking properties of CGA. Molecular docking outcomes revealed the positioning of CGA/CUR is driven by "aromatic interactions" with Trp β₁180 and Tyr α₂540. These interactions are modulated by the structural constraints such as number of hydroxyl groups and their methylation status directing the biophenols to the amyloidogenic core. The results are applicable to formulation of small-molecule nutraceuticals for treatment of conformational diseases.